HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

Why It Matters

Catheter‑directed therapy delivers a substantial outcome benefit without added bleeding, positioning it as a potential new standard for intermediate‑risk PE management.

Key Takeaways

• 61% risk reduction in decompensation at 7 days
• Number needed to treat: 16 patients
• No significant increase in major bleeding
• Trial enrolled 544 intermediate‑risk PE patients
• Findings may reshape PE management guidelines

Pulse Analysis

Pulmonary embolism remains a leading cause of cardiovascular mortality, and patients classified as intermediate‑risk present a therapeutic dilemma. Traditional systemic thrombolysis, as demonstrated in the original PEITHO trial, can prevent deterioration but carries a high price in hemorrhagic stroke and extracranial bleeding. This safety concern left clinicians reliant on anticoagulation alone, despite lingering fears of rapid decompensation in a sizable subset of patients. The need for a middle‑ground solution set the stage for catheter‑directed approaches that target clot burden while limiting systemic exposure.

HI‑PEITHO addressed that gap by randomizing 544 patients to either standard heparin anticoagulation or ultrasound‑enhanced, catheter‑directed alteplase plus heparin. The intervention arm achieved a 61% relative risk reduction in the primary composite endpoint, driven primarily by fewer cases of cardiorespiratory collapse (3.7% vs 10.3%). With a number needed to treat of 16 and no statistically significant rise in ISTH‑defined major bleeding, the trial demonstrates that low‑dose, localized thrombolysis can be both effective and safe. Procedurally, the mean infusion lasted seven hours, delivering roughly 9 mg of alteplase per catheter, a stark contrast to the 100 mg systemic doses that previously sparked safety alarms.

The implications for practice are immediate. Guideline committees are already citing HI‑PEITHO as pivotal evidence for updating the 2026 acute PE recommendations, especially for patients falling into category D (incipient cardiopulmonary failure). However, adoption will hinge on hospital infrastructure, operator expertise, and cost‑effectiveness analyses, as the trial’s strict enrollment excluded nearly 87% of screened candidates. Ongoing registries and longer‑term follow‑up will be essential to confirm durability of benefit and to refine patient‑selection algorithms, ensuring that the promise of catheter‑directed therapy translates into broader, real‑world improvements in PE outcomes.